Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.
Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.
In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
FDA approval decision expected in the second quarter of 2020.
Prostate cancer is the second most common cancer in men after skin cancer.
Drug to treat prostate cancer is expected to produce a major windfall for two pharma makers.